secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0000950170-23-022236
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health Q1 2023 revenue down 12% to $376K; gross profit up 61% to $113K
----------------------------------------------------------------------------

- Net loss $2.1M vs $2.2M prior year; cash $5.2M at quarter end.
- Gross margin improved 61% on 17% higher ASP and 15% lower variable cost.
- Revenue decline of 12% due to 27% unit sales drop and termination of less profitable retail channels.
- Innovation pipeline expanded: vagus nerve stimulation program; collaboration with Feinstein Institute.
- Closed $5M financing in Feb 2023; B2B sales portal and price increases implemented in April 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017023022236/0000950170-23-022236-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017023022236/tivc-20230515.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-022236

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer